Is ENGN or ESLA more undervalued in 2026?

CirclFi compares enGene Therapeutics Inc. (ENGN) and Estrella Immunopharma, Inc. (ESLA) using 13 institutional-grade valuation models. ENGN has a Quality of Company score of 4.1/10 while ESLA scores 3.1/10.

Which is a better buy — ENGN or ESLA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do ENGN and ESLA valuations compare?

ENGN at $1.85 and ESLA at $1.09 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

ENGN vs ESLA Valuation Comparison 2026 — Intrinsic Value Analysis

ENGN

Biological Products, (No Diagnostic Substances)

enGene Therapeutics Inc.

Quality

4.1

out of 10

Value Trap

SAFE

Price

$1.85

Last close

Models

8/13

Active

ESLA

Biological Products, (No Diagnostic Substances)

Estrella Immunopharma, Inc.

Quality

3.1

out of 10

Value Trap

SAFE

Price

$1.09

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	ENGN Fair Value	ENGN Upside	ESLA Fair Value	ESLA Upside
Bayesian DCF	Intrinsic	$0.54	-70.9%	$0.32	-70.3%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$1.93	+4.2%	$0.01	-98.9%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	—	—	$1.51	+35.0%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for ENGN vs ESLA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ENGN vs ESLA — Which Stock Is More Undervalued?

ENGN scores higher with a 4.1/10 quality rating vs ESLA's 3.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing enGene Therapeutics Inc. (ENGN) and Estrella Immunopharma, Inc. (ESLA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ENGN currently trades at $1.85 with a QOC of 4.1/10, while ESLA trades at $1.09 with a QOC of 3.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).